Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
2.
Cell Mol Immunol ; 11(2): 160-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24240123

ABSTRACT

In allogeneic stem cell transplantation (SCT), natural killer (NK) cells lacking their cognate inhibitory ligand can induce graft-versus-leukemia responses, without the induction of severe graft-versus-host disease (GVHD). This feature can be exploited for cellular immunotherapy. In this study, we examined selective expansion of NK cell subsets expressing distinct killer immunoglobulin-like receptors (KIRs) within the whole human peripheral blood NK cell population, in the presence of HLA-Cw3 (C1) or Cw4 (C2) transfected K562 stimulator cells. Coculture of KIR(+) NK cells with C1 or C2 positive K562 cells, in the presence of IL-2+IL-15, triggered the outgrowth of NK cells that missed their cognate ligand. This resulted in an increased frequency of alloreactive KIR(+) NK cells within the whole NK cell population. Also, after preculture with K562 cells lacking their cognate ligand, we observed that this alloreactive NK population revealed higher numbers of CD107(+) cells when cocultured with the relevant K562 HLA-C transfected target cells, as compared to coculture with untransfected K562 cells. This enhanced reactivity was confirmed using primary leukemic cells as target. This study demonstrates that HLA class I expression can mediate the skewing of the NK cell repertoire and enrich the population for cells with enhanced alloreactivity towards leukemic target cells. This feature may support future clinical applications of NK cell-based immunotherapy.


Subject(s)
Immunotherapy/methods , Killer Cells, Natural/immunology , Leukemia/immunology , Leukemia/therapy , Stem Cell Transplantation , Cell Proliferation , Coculture Techniques , Graft vs Leukemia Effect/genetics , Graft vs Leukemia Effect/immunology , HLA-C Antigens/genetics , HLA-C Antigens/metabolism , Humans , Immunotherapy/trends , Interleukin-15/immunology , Interleukin-2/immunology , K562 Cells , Lysosomal-Associated Membrane Protein 1/metabolism , Transgenes/genetics , Transplantation, Homologous
3.
World J Urol ; 26(1): 103-10, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17982751

ABSTRACT

Metabolic gene polymorphisms have previously been suggested as risk factors for renal cell carcinoma (RCC). These polymorphisms are involved in activation or detoxification of carcinogens in cigarette smoke which is another RCC risk factor. We evaluated gene-environment interactions between CYP1A1, GSTmicro1 and smoking in a large population-based RCC case group. The Netherlands Cohort Study on diet and cancer (NLCS) comprises 120,852 persons who completed a questionnaire on smoking and other risk factors at baseline. After 11.3 years of follow-up, 337 incident RCC cases were identified. DNA was collected for 245 cases. In a case-only analysis, interaction-odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using logistic regression. We observed a moderate, not statistically significant, interaction between current smoking and CYP1A1*2C (OR 1.42; 95% CI 0.70-2.89) and GSTmicro1 null (OR 1.35; 95% CI 0.65-2.79). For current smokers with both a variant (heterozygous or homozygous) in CYP1A1 and GSTmicro1 null, risk was also increased (OR 1.63; 95% CI 0.63-4.24). No interaction was observed between ever smokers, smoking duration (increments of 10 smoking years) or amount (increments of 5 cigarettes/day) and CYP1A or GSTmicro1. Our results show a modest trend towards a statistically significant gene-environment interaction between CYP1A1, GSTmicro1 and smoking in RCC. This could indicate that RCC risk among smokers might be more increased with the CYP1A1*2C genotype, GSTmicro1 null, or both a CYP1A1 variant and GSTmicro1 null.


Subject(s)
Biotransformation/genetics , Carcinogens/pharmacokinetics , Cytochrome P-450 CYP1A1/genetics , Glutathione Transferase/genetics , Kidney Neoplasms/genetics , Polymorphism, Genetic , Smoking/adverse effects , Aged , Carcinoma, Renal Cell/epidemiology , Carcinoma, Renal Cell/etiology , Carcinoma, Renal Cell/genetics , DNA, Neoplasm/genetics , Electrophoresis, Agar Gel , Female , Follow-Up Studies , Genotype , Humans , Incidence , Kidney Neoplasms/epidemiology , Kidney Neoplasms/etiology , Male , Middle Aged , Netherlands/epidemiology , Polymerase Chain Reaction , Prospective Studies , Risk Factors
4.
Eur J Cancer ; 42(18): 3219-27, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16934975

ABSTRACT

AIM: E-cadherin plays a role in carcinogenesis. For two genetic polymorphisms in the gene (CDH1) promoter, a reduced transcription has been reported: a C/A single nucleotide polymorphism (SNP) and a G/GA SNP at -160 bp and -347 bp, respectively, upstream of the transcriptional start site. We studied the association between both polymorphisms and the risk of bladder cancer. METHODS: One hundred and ninety-seven patients with bladder cancer and 344 population controls were genotyped and haplotyped for both SNPs. RESULTS: A borderline significantly increased risk for bladder cancer was found for A allele carriers (OR 1.36; 95% CI: 0.96-1.94). We did not find any association between the -347 G/GA SNP and bladder cancer. Haplotype analyses did not yield much stronger associations with bladder cancer than the -160 C/A genotype analyses. CONCLUSION: This study supports earlier suggestions that the -160 C/A SNP in the CDH1 promoter is a risk factor for bladder cancer.


Subject(s)
Cadherins/genetics , Polymorphism, Genetic/genetics , Urinary Bladder Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Gene Frequency , Genotype , Haplotypes/genetics , Humans , Male , Middle Aged , Risk Factors
5.
BJU Int ; 97(4): 852-5, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16536786

ABSTRACT

OBJECTIVE To determine whether a common single nucleotide polymorphism (SNP) in the ADRA1A gene encoding the alpha(1A)-adrenoceptor modifies the short- and long-term efficacy of alpha(1)-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia (BPH). PATIENTS AND METHODS For 254 patients with BPH and/or lower urinary tract symptoms who received alpha(1)-adrenergic antagonists for > or = 3 months, the ADRA1A genotype at position 1475 of the coding region was determined. The patients' short-term response to treatment was determined for four outcome measures, i.e. the International Prostate Symptom Score (IPSS), the IPSS quality-of-life score, peak urinary flow rate, and obstruction grade, stratified by genotype. Eventual BPH-related invasive therapy was used as the outcome for assessing the long-term response to treatment. Genetic variants at positions 834, 896, 898 and 1831 were too rare to be considered in the analysis. RESULTS There were no significant differences for the genotype strata in three of the four outcome measures. Patients with the CC genotype responded significantly better in quality-of-life perception than patients with the CT or TT genotype. There were also no significant differences in the risk of BPH-related invasive therapy among the three genotypes. CONCLUSIONS The 1475C-->T SNP in the ADRA1A gene does not modify the short- and long-term efficacy of alpha(1)-adrenoceptor antagonists for treating BPH. There was a small effect on perceived quality of life but this was not reflected in other variables that measured the treatment response more directly.


Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Prostatic Hyperplasia/drug therapy , Receptors, Adrenergic, alpha-1/genetics , Aged , Humans , Male , Middle Aged , Polymorphism, Genetic/genetics , Polymorphism, Single Nucleotide/genetics , Prostatic Hyperplasia/genetics , Quality of Life , Risk Factors , Treatment Outcome
6.
BMC Cancer ; 5: 57, 2005 Jun 02.
Article in English | MEDLINE | ID: mdl-15932632

ABSTRACT

BACKGROUND: Biallelic von Hippel-Lindau (VHL) gene defects, a rate-limiting event in the carcinogenesis, occur in approximately 75% of sporadic clear-cell Renal Cell Carcinoma (RCC). We studied the VHL mutation status in a large population-based case group. METHODS: Cases were identified within the Netherlands cohort study on diet and cancer, which includes 120,852 men and women. After 11.3 years of follow-up, 337 incident cases with histologically confirmed epithelial cancers were identified. DNA was isolated from paraffin material collected from 51 pathology laboratories and revised by one pathologist, leaving material from 235 cases. VHL mutational status was assessed by SSCP followed by direct sequencing, after testing SSCP as a screening tool in a subsample. RESULTS: The number of mutations was significantly higher for clear-cell RCC compared to other histological types. We observed 131 mutations in 114 out of 187 patients (61%) with clear-cell RCC. The majority of mutations were truncating mutations (47%). The mean tumor size was 72.7 mm for mutated tumors compared to 65.3 mm for wildtype tumors (p = 0.06). No statistically significant differences were observed for nuclear grade, TNM distribution or stage. In other histological types, we observed 8 mutations in 7 out of 48 patients (15%), 1 mutation in 1 of 6 oncocytoma, 3 mutations in 2 of 7 chromophobe RCC, 2 mutations in 2 of 30 papillary RCC, no mutations in 1 collecting duct carcinoma and 2 mutations in 2 of 4 unclassified RCC. CONCLUSION: VHL mutations were detected in 61% of sporadic clear-cell RCC. VHL mutated and wildtype clear-cell RCC did not differ with respect to most parameters.


Subject(s)
Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , Mutation , Von Hippel-Lindau Tumor Suppressor Protein/genetics , Aged , Carcinoma, Renal Cell/metabolism , Cell Line, Tumor , Codon , Cohort Studies , DNA/chemistry , DNA Mutational Analysis , DNA Primers/chemistry , Female , Humans , Male , Middle Aged , Netherlands , Polymorphism, Single-Stranded Conformational , Sequence Analysis, DNA , Surveys and Questionnaires
7.
Prostate ; 54(1): 50-7, 2003 Jan 01.
Article in English | MEDLINE | ID: mdl-12481255

ABSTRACT

BACKGROUND: In this study, we evaluate the pattern of allelic imbalance (AI) in both sporadic prostate cancer (SPC) and hereditary prostate cancer (HPC) at loci that frequently show allelic imbalance in sporadic prostate cancer, or are believed to have a putative role in the disease. METHODS: DNA obtained from 35 sporadic tumors and 46 hereditary tumors were tested for AI, by using a panel of 35 microsatellite markers. RESULTS: Chromosomal regions that display high frequencies of AI (>or=30%) in HPC include 1q, 5q, 7q, 8p, 13q, 16q, 17q, 18q, and 20q. In SPC, high frequencies of AI were found at 5q, 7q, 8p, 10q, 13q. Main differences (delta >or= 20%) in AI between HPC and SPC were at 1q, 10q, 17q, 18q, and 20q. CONCLUSION: AI at the prostate cancer susceptibility loci HPC1, PCaP, and HPC20 was seen more often in HPC compared with SPC. It appears that there are marked differences in the pattern of AI between sporadic and hereditary PCa.


Subject(s)
Allelic Imbalance/genetics , DNA, Neoplasm/genetics , Genes, Tumor Suppressor , Prostatic Neoplasms/genetics , Aged , Genetic Markers , Humans , Male , Microsatellite Repeats , Middle Aged , Prostatic Neoplasms/pathology
8.
Int J Cancer ; 100(6): 683-5, 2002 Aug 20.
Article in English | MEDLINE | ID: mdl-12209606

ABSTRACT

E-cadherin plays a major role in intercellular adhesion, cell polarity and tissue architecture. We determined the relative risk of PCa associated with a previously reported C/A SNP at -160 bp relative to the transcription-start site of the E-cadherin gene promoter. Eighty-two PCa patients and 188 controls were genotyped. Genotype and allele frequencies differed significantly among cases and controls. A-allele carriers had a higher relative risk of PCa (OR = 3.6, 95% CI 2.0-6.4) compared to C-only carriers. AC and AA genotypes had an increased risk of PCa (OR = 3.8, 95% CI 2.1-6.8 and OR = 1.7, 95% CI 0.4-6.6, respectively) compared to CC genotypes.


Subject(s)
Cadherins/genetics , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Prostatic Neoplasms/genetics , Aged , Alleles , Case-Control Studies , Genotype , Humans , Male , Middle Aged , Risk
9.
J Urol ; 167(2 Pt 1): 621-3, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11792931

ABSTRACT

PURPOSE: Increased length of the CAG repeat in the androgen receptor gene may be related to male subfertility. Expansion to 38-62 CAG repeats leads to the neurodegenerative disorder with male infertility called Kennedy's disease. Recently it was suggested that slight expansion is related to male subfertility. In this study we investigated the association of male subfertility with the length of CAG repeats in the androgen receptor. MATERIALS AND METHODS: CAG repeat length in the androgen receptor gene was investigated in 75 subfertile men, who were mainly candidates for intracytoplasmic sperm injection. Sperm parameters varied from azoospermia to severe oligoasthenoteratozoospermia. The control group consisted of 70 men who predominantly had bladder cancer. DNA was isolated from peripheral blood and genotyping was performed with polymerase chain reaction based methods. RESULTS: No statistically significant difference in the mean length of the CAG repeat plus or minus standard deviation was noted in subfertile men and controls (22.2 +/- 3.1 and 21.7 +/- 3.4, respectively). The length of the CAG repeat in the androgen receptor was not related to the degree of impaired spermatogenesis or clinical characteristics of the subfertile men. CONCLUSIONS: Increased length of CAG repeats in the androgen receptor gene is not a risk factor for male subfertility.


Subject(s)
Infertility, Male/genetics , Receptors, Androgen/genetics , Trinucleotide Repeats , Humans , Infertility, Male/blood , Infertility, Male/epidemiology , Male , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...